CDT Equity (CDT) EBT (2022 - 2026)
CDT Equity's (CDT) quarterly EBT came in at -$4.1 million in Q1 2026, up 13.85% YoY from -$3.6 million in Q1 2025, and up 79.66% on a QoQ basis from -$19.9 million in Q4 2025.
CDT Equity (CDT) EBT (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of EBT data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly EBT rose 13.85% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.2 million (down 43.06% YoY) and the FY2025 annual result came in at -$45.8 million, down 114.77% from the prior year.
- EBT advanced to -$4.1 million in Q1 2026, from -$19.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of $751312.0 in Q4 2022 to a low of -$42.9 million in Q1 2024.
- A 5-year average of -$6.3 million and a median of -$4.1 million in 2026 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT soared 161.86% — and 2024, when it slumped 27484.49%.
- Tracing CDT's EBT over 5 years: stood at $751312.0 in 2022, then slumped by 224.98% to -$939000.0 in 2023, then plunged by 894.36% to -$9.3 million in 2024, then slumped by 113.56% to -$19.9 million in 2025, then soared by 79.66% to -$4.1 million in 2026.
- The last three EBT figures came in at -$4.1 million (Q1 2026), -$19.9 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 81.49 Mn |
| 10 | CDT Equity | 1.61 Mn | 1.61 Mn | - | -4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.54 Mn |
| Mar 31, 2026 | -4.06 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -4.71 Mn |
| Dec 31, 2024 | -9.34 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Mar 31, 2024 | -42.95 Mn |
| Dec 31, 2023 | -939,000.00 |
| Sep 30, 2023 | -679,000.00 |
| Jun 30, 2023 | -130,976.00 |
| Mar 31, 2023 | 156,826.00 |
| Dec 31, 2022 | 751,312.00 |
| Sep 30, 2022 | 363,560.00 |
| Jun 30, 2022 | -87,835.00 |
| Mar 31, 2022 | -253,536.00 |